Education
About Us
Working with TipRanks
Follow Us
Livzon Pharmaceutical Group Inc Class H (HK:1513)
:1513
RESEARCH TOOLSreports
Total Valuation
Livzon Pharmaceutical Group has a market cap or net worth of $30.08B. The enterprise value is HK$19.65B.
Market Cap$30.08B
Enterprise ValueHK$19.65B
Share Statistics
Livzon Pharmaceutical Group has 307,052,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding307,052,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Livzon Pharmaceutical Group’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee1.37M
Profits Per Employee209.29K
Employee Count9,067
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Livzon Pharmaceutical Group is ―. Livzon Pharmaceutical Group’s PEG ratio is ―.
PE Ratio―
PS Ratio1.76
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Livzon Pharmaceutical Group had revenue of 12.43B and earned 1.95B in profits. Earnings per share was 2.10.
Revenue12.43B
Gross Profit7.66B
Operating Income2.42B
Pretax Income2.38B
Net Income1.95B
EBITDA3.33B
Earnings Per Share (EPS)2.10
Cash Flow
In the last 12 months, operating cash flow was 2.57B and capital expenditures 0.00, giving a free cash flow of 2.03B billion.
Operating Cash Flow2.57B
Free Cash Flow2.03B
Free Cash Flow per Share6.61
Dividends & Yields
Livzon Pharmaceutical Group pays an annual dividend of HK$1.457, resulting in a dividend yield of 5.71%
Dividend Per ShareHK$1.457
Dividend Yield5.71%
Payout Ratio62.59%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.63
52-Week Price Change9.53%
50-Day Moving Average26.18
200-Day Moving Average26.03
Relative Strength Index (RSI)53.03
Average Volume (3m)1.07M
Important Dates
Livzon Pharmaceutical Group upcoming earnings date is Apr 23, 2025, TBA Not Confirmed.
Last Earnings DateMar 26, 2025
Next Earnings DateApr 23, 2025
Ex-Dividend DateJul 08, 2024
Financial Position
Livzon Pharmaceutical Group as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Livzon Pharmaceutical Group has paid 485.07M in taxes.
Income Tax485.07M
Effective Tax Rate―
Enterprise Valuation
Livzon Pharmaceutical Group EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Livzon Pharmaceutical Group has $10.81B in cash and marketable securities with ¥275.58M in debt, giving a net cash position of -$8.34B billion.
Cash & Marketable Securities$10.81B
Total Debt¥275.58M
Net Cash-$8.34B
Net Cash Per Share-$27.16
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Livzon Pharmaceutical Group is $22.98, which is 11.43% higher than the current price. The consensus rating is Moderate Sell
Price Target$22.98
Price Target Upside-13.63% Downside
Analyst ConsensusModerate Sell
Analyst Count0
Revenue Growth Forecast-6.98%
EPS Growth Forecast4.32%